FORT WAYNE, Ind. A terminal diagnosis isn’t keeping a veteran from seeing Washington D.C. one last time.
Category: Banking
Collegium Pharmaceutical Inc (COLL) Shares Bought by Franklin Resources Inc.
Franklin Resources Inc. boosted its position in shares of Collegium Pharmaceutical Inc by 98.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,797,902 shares of the specialty pharmaceutical company’s stock after buying an additional 890,868 shares during the period.
US stocks slip further from record highs as banks decline
U.S. stocks are starting lower for the second time in three days as most parts of the market slip. Banks, which surged last week as interest rates quickly rose, are returning some of their gains.
AbbVie Inc (ABBV) Stake Lowered by Formidable Asset Management LLC
Formidable Asset Management LLC reduced its position in AbbVie Inc by 3.2% during the fourth quarter, Holdings Channel reports. The fund owned 4,112 shares of the company’s stock after selling 134 shares during the period.
Puma Biotechnology Inc (PBYI) Rating Reiterated by Citigroup Inc.
‘s stock had its “buy” rating reissued by research analysts at Citigroup Inc. in a research report issued on Saturday. They currently have a $88.00 price target on the biopharmaceutical company’s stock.
FTSE 100 movers: Burberry shines on update but Pearson tanks
London’s FTSE 100 was up 0.2% to 7,235.79 in afternoon trade, with updates from Burberry and Pearson in focus. Luxury retailer Burberry was the standout gainer after it reported 4% growth in underlying retail sales for the third quarter, boosted by a return to growth for the Asia Pacific region but with the Americas still in decline.
ACADIA Pharmaceuticals Inc. (ACAD) Receives “Outperform” Rating from Cowen and Company
Cowen and Company currently has a $42.00 target price on the biopharmaceutical company’s stock. Several other equities analysts have also weighed in on the stock.
Exelixis Inc. (EXEL) Stake Raised by Swiss National Bank
Swiss National Bank increased its position in shares of Exelixis Inc. by 1.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission . The fund owned 367,300 shares of the biotechnology company’s stock after buying an additional 5,600 shares during the period.
Press release distribution, EDGAR filing, XBRL, regulatory filings
… accomplishments of seven Key … )–The Assistance Fund helps primary biliary cholangitis patients with copays, health insurance premiums & incidental medical expenses through its Primary Biliary Chola… )–DigitalTrends.com,the premier site for …